US › Healthcare

Regenxbio Inc (RGNX)

US · Healthcare · Biotechnology

$6.92-3.28%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$108.0M

Revenue YoY

+405.7%

Net profit

$22.7M

EPS

$0.43

EPS estimate

$0.12

Net margin

21.0%

EPS came in at 0.43 against a street estimate of 0.12 — a beat of 258.3%.

Key statistics

Market cap

$532.7M

Forward P/E

0.0

P/B

6.89

Book value

$1.32

EPS (TTM)

$-3.78

52-week high

$16.19

52-week low

$5.46

50-day MA

$9.08

200-day MA

$9.72

Beta

1.13

Analyst view

Analysts rate Regenxbio Inc a buy (10 buy, 2 hold, 0 sell out of 12) with an average price target of $23.58.

Shareholding

Insiders

6.55%

Institutions

65.26%

Largest institutional holders

Fund	Stake
BlackRock Inc	9.74%
Redmile Group, LLC	6.65%
State Street Corp	4.52%
JPMorgan Chase & Co	3.37%
Vanguard Capital Management, LLC	3.21%
Morgan Stanley - Brokerage Accounts	2.97%
The Goldman Sachs Group Inc	2.16%
AQR Capital Management LLC	2.10%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Regenxbio Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.